US Patent

US11083724 — Rimegepant for CGRP related disorders

Method of Use · Assigned to Biohaven Pharmaceutical Ireland DAC · Expires 2039-03-25 · 13y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of treating CGRP-related disorders, such as migraine, using rimegepant or a pharmaceutically acceptable salt thereof.

USPTO Abstract

Disclosed are methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof rimegepant or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising rimegepant and kits including the pharmaceutical compositions and instructions are also disclosed.

Drugs covered by this patent

Nurtec Odt (Rimegepant Sulfate) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2718`	—	Nurtec Odt

Patent Metadata

Patent number: US11083724
Jurisdiction: US
Classification: Method of Use
Expires: 2039-03-25
Drug substance claim: No
Drug product claim: Yes
Assignee: Biohaven Pharmaceutical Ireland DAC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.